Anticoagulant therapy for atrial fibrillation and high risk of thromboembolic events in certain Russian regions in 2023
Open Access
- 8 August 2025
- journal article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (6) , 6273
Abstract
Aim. To conduct a retrospective analysis of anticoagulation prescription rate, including direct oral anticoagulants (DOAC), to patients with atrial fibrillation and high risk of thromboembolic events (TEEs) in certain Russian regions as of December 31, 2023.Material and methods. The analyzed group of patients was formed based on the information contained in the Webiomed predictive analytics platform (OOO K-Sky, Petrozavodsk, Russia). The information was presented as the extracted depersonalized anonymized data from the electronic health records of patients aged ≥18 years, attached to medical facilities of 17 Russian subjects (n=107561, men 37,8%, mean age 74,5±8,5 years, mean CHA2DS2-VASc score of 3,6±1,2) extracted by the continuous sampling method.Results. Anticoagulation prescription rate in the group as a whole was 53,7%, while the DOAC share in its structure was 87,0%. Acetylsalicylic acid for TEE prevention was prescribed in 10,6% of cases. With an increase of non-gender-specific CHA2DS2-VASc score, the percentage of people receiving anticoagulation increased — from 49,7% with 2 points to 73,9% with 8 points. Anticoagulation was prescribed to patients aged ≥75 years significantly less often (49,1%, pConclusion. The results of retrospective analysis indicate improvement in anticoagulation prescription rate for atrial fibrillation and a high risk of TEEs in certain Russian regions. Compared to a similar study for 2016-2019, in 2023 this indicator increased from 34,8% to 53,7%. The share of DOACs in anticoagulant therapy structure also increased significantly — from 52,0% to 87,0%. At the same time, oral anticoagulation rate in this cohort of patients still does not meet the requirements of current clinical guidelines.Keywords
This publication has 19 references indexed in Scilit:
- 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)European Heart Journal, 2024
- Correction to: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesCirculation, 2024
- Patients with atrial fibrillation and a low risk of thromboembolic events: prescription rate of anticoagulant therapy according to a retrospective analysisRussian Journal of Cardiology, 2023
- 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)Russian Journal of Cardiology, 2021
- 2020 Clinical guidelines for Atrial fibrillation and atrial flutterRussian Journal of Cardiology, 2021
- Central directions for reducing cardiovascular mortality: what can be changed today?Russian Journal of Cardiology, 2020
- Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term RegistryEP Europace, 2019
- A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulationEuropean Heart Journal, 2018
- Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR ® ) PINNACLE RegistryJournal of the American Heart Association, 2017
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 2014